The pathophysiology of dry age-related macular degeneration (AMD) and specifically
geographic atrophy (GA) has been linked to the complement cascade. This cascade is part …

Age-related macular degeneration (AMD) is the leading cause of vision loss and visual
impairment in people over 50 years of age. In the current therapeutic landscape, intravitreal …

Gene therapies aim to deliver a therapeutic payload to specified tissues with underlying
protein deficiency. Since the 1990s, gene therapies have been explored as potential …

In 2001, the first large animal was successfully treated with a gene therapy that restored its
vision. Lancelot, the Briard dog that was treated, suffered from a human childhood blindness …

The complement alternative pathway (AP) is implicated in numerous diseases affecting
many organs, ranging from the rare hematological disease paroxysmal nocturnal …

Purpose: To expand the use of human retinal organoids from induced pluripotent stem cells
(iPSCs) as an in vitro model of the retina for assessing gene therapy treatments, it is …

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in
the elderly population. AMD is characterized in its late form by neovascularization (wet type) …

Age-related macular degeneration (AMD) is the most common cause of irreversible vision
loss among the elderly in Western communities, with an estimated global prevalence of 10 …

With advances in gene‐based therapies for heritable retinal diseases, primary eye care
clinicians should be informed on ocular genetics topics. This cross‐sectional survey …

Gene therapy has witnessed substantial advancements in recent years, becoming a
constructive tactic for treating various human diseases. This review presents a …